Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Hum Vaccin Immunother. 2020;16(1):109-111. doi: 10.1080/21645515.2019.1636598. Epub 2019 Jul 24.

Abstract

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.

Keywords: Acute myeloid leukemia; IL-2; histamine dihydrochloride; immunotherapy; normal karyotype; relapse prevention.

Publication types

  • Clinical Trial, Phase III
  • Clinical Trial, Phase IV
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Chromosome Aberrations
  • Data Analysis
  • Databases, Factual
  • Histamine / therapeutic use*
  • Humans
  • Immunotherapy*
  • Interleukin-2 / therapeutic use*
  • Karyotype
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / therapy*
  • Middle Aged
  • Recurrence
  • Secondary Prevention / methods
  • Young Adult

Substances

  • Interleukin-2
  • Histamine

Grant support

This work was supported by Cancerfonden [CAN2018/582];Cancerfonden [CAN 2016/351] and Vetenskapsrådet [2016-01928].